CoChat

A comparison of panitumumab and cetuximab in the treatment of KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis

Liu, Tong, Jiang, Shuai, Teng, Xue, Zhong, Lu, Liu, Mengmeng, Jin, Yao, Dong, Mei · 2023 · Immunopharmacology and Immunotoxicology

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Aim Cetuximab and panitumumab are common antibodies against epidermal growth factor receptor (EGFR) that can be used in combination with chemotherapy for the treatment of metastatic colorectal cancer (mCRC). Although these two drugs are considered to be very similar, differences in the efficacy and safety of cetuximab and panitumumab are still unclear. We conducted this meta-analysis to explore the effects and adverse reactions of cetuximab and panitumumab in the treatment of mCRC.Methods We searched PubMed, the Cochrane Library, Embase, Web of Science, China national knowledge infrastructure (CNKI) and WanFang databases to identify records related to the efficacy and safety of cetuximab and panitumumab in the treatment of mCRC. The search terms were “cetuximab,” “panitumumab,” and “colorectal cancer.” The deadline of searching was April 2022. Review manager 5.4 software was used to perform the statistical analysis for this meta-analysis. Pooled hazard ratio (HR) with 95% confidence intervals (CI) were calculated to evaluate the overall survival (OS) and progression free survival (PFS) of cetuximab and panitumumab in the treatment of mCRC.Results There was no significant difference in OS, PFS, and response rate (RR) between cetuximab arm and panitumumab arm (OS: HR = 0.91, 95% CI = 0.81–1.03, p = .14; PFS: HR = 0.92, 95% CI = 0.83–1.02, p = .11; RR: OR = 1.22, 95% CI = 0.96–1.61, p = .14). We also did not observe any statistical difference between both arms in incidence of acneiform rash, severe acneiform rash, diarrhea, and severe diarrhea (acneiform rash: OR = 1.09, 95% CI = 0.84–1.42, p = .51; severe acneiform rash: OR = 1.50, 95% CI = 0.80–2.81, p = .21; diarrhea: OR = 1.08, 95% CI = 0.82–1.42, p = .58; severe diarrhea: OR = 0.90, 95% CI = 0.44–1.84, p = .77). The incidence of paronychia was decreased in the panitumumab arm, but that of hypomagnesemia and severe hypomagnesemia were decreased in the cetuximab arm. (paronychia: OR = 0.74, 95% CI = 0.55–1.00, p = .05; hypomagnesemia: OR = 1.85, 95% CI =1.41–2.41, p < .00001; severe hypomagnesemia: OR = 2.66, 95% CI = 1.52–4.67, p = .0006).Conclusion There was no significant difference in OS, PFS and RR between the cetuximab arm and panitumumab arm in the treatment of mCRC. For adverse reactions, the incidence of paronychia was decreased in the panitumumab arm, and the incidence of hypomagnesemia was deceased in the cetuximab arm.

Overview

Integrity signals

Registry

Crossref · 10.1080/08923973.2022.2112222

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 18 references

Research works printed but not linked: 4

  1. Krawczyk PA, 2014, Contemp Oncol (Pozn), 18, 7
  2. Merck KGaA Press Release. 2017. Available from: https://www.ots.at/presseaussendung/OTE_20170302_OTE0001/nice-expands-positive-recommendation-for-erbitux-as-fifirst-line-treatment-for-ras-wild-type-mcrc (accessed March 2018).
  3. Liu T, 2020, Evid Based Complement Alternat Med, 2020, 1
  4. Yamaguchi T, 2016, Anticancer Res, 36, 3531

Cited by

See all 17

Metadata

Authors
Liu, T., Jiang, S., Teng, X., Zhong, L., Liu, M., Jin, Y., & Dong, M.
Affiliations
Third Affiliated Hospital of Harbin Medical University (CN)
Corresponding author
Dong, Mei
Venue
Immunopharmacology and Immunotoxicology
Published
2022-08-18
Volume
45
Issue
1
Pages
1-9
ISSN
  • 0892-3973 (ISSN-L)
  • 1532-2513
OpenAlex
W4290803826
Cited by
17
References
18
Citations by year
2026: 3 · 2025: 7 · 2024: 4 · 2023: 3
FWCI
0.43
Type
journal article
Language
en
Open access
closed
Locations
  • Immunopharmacology and Immunotoxicology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
panitumumab, cetuximab, metastatic colorectal cancer, KRAS wild-type, EGFR inhibitors, anti-EGFR antibody therapy, overall survival, progression-free survival, acneiform rash, diarrhea, drug safety, treatment efficacy, combination chemotherapy, response rate, time to progression, time to response, treatment response time
MeSH terms
Cetuximab, Panitumumab, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Colonic Neoplasms, Exanthema, Humans, Paronychia, Rectal Neoplasms, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A comparison of panitumumab and cetuximab in the treatment of KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1080/08923973.2022.2112222
The paper
Liu, T., Jiang, S., Teng, X., Zhong, L., Liu, M., Jin, Y., & Dong, M. (2023). A comparison of panitumumab and cetuximab in the treatment of KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Immunopharmacology and Immunotoxicology. https://doi.org/10.1080/08923973.2022.2112222

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.